Core Viewpoint - Scinai Immunotherapeutics Ltd. has received expanded support from the Israel Innovation Authority for its robotic aseptic fill & finish platform, with a total grant budget of NIS 5 million over two years, of which approximately 66% is non-dilutive funding [1] Group 1: Project and Funding Details - The project aims to advance a fully automated robotic-arm aseptic fill & finish system compliant with EU GMP Annex 1 standards, with validation expected to be completed in Q3 2026 [1] - The funding will support the acquisition and validation of the robotic system, enhancing Scinai's clinical manufacturing capabilities [1] Group 2: Strategic Developments - The investment is part of Scinai's strategy to modernize its CDMO capabilities following the acquisition of Recipharm Israel Ltd. and a strategic collaboration agreement with Recipharm [1] - The collaboration with Recipharm provides a pathway for clients to transition from early clinical development to late-stage and commercial manufacturing within Recipharm's global network [1] Group 3: Operational Enhancements - Robotic aseptic processing is expected to reduce human intervention, enhance reproducibility, and strengthen contamination control in sterile manufacturing [1] - The new platform will support complex biologics programs and align with the expansion of Scinai's development and manufacturing footprint [1] Group 4: Future Opportunities - The company is monitoring a potential new IIA program to support industrial CAPEX investments, which could further enhance capabilities at its Yavne small-molecule site [1]
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform